Pegaptanib Ophthalmic Dosage

Usual Adult Dose for Macular Degeneration

0.3 mg via intravitreal injection into the affected eye once every 6 weeks.

Comments: No additional benefit has been demonstrated with dose levels above 0.3 mg.

Use: Treatment of neovascular (wet) age-related macular degeneration (AMD).

Renal Dose Adjustments

Data not available.

Liver Dose Adjustments

Data not available.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available.

Other Comments

Administration Advice:

• Inspect drug prior to administration; do not use if visible particulates or discoloration are observed.
• Consult the manufacturer product information for injection procedure instructions.

• Store in the refrigerator at 2 to 8 degrees Celsius (36 to 46 Fahrenheit); do not freeze or shake vigorously.

• Studies have revealed no apparent difference in the plasma pharmacokinetics of this drug when used alone or in combination with photodynamic therapy (PDT).
• Overdosage: No additional adverse effects have been noted with doses up to 10 times the recommended dosage.

• Optic nerve head perfusion (immediately after drug administration)
• Intraocular pressure (within 30 minutes of and during the week after drug administration)
• Infection/inflammation, endophthalmitis (during the week after drug administration)

• If your eye becomes red, sensitive to light, painful, or develops a change in vision during the week after receiving an injection of this drug, immediately contact your healthcare provider.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer